Survalence Biosciences logo

Survalence Biosciences

Reading the carcinogens left on your DNA

BostonHealthPre-product

PITCHING AT THE BOSTON NIGHT ON 9 SEPTEMBER 2026

Cancer prevention advice is mostly generic, because nobody can tell you which carcinogens you personally have been exposed to. Survalence's CaSe assay identifies the chemicals bound to a person's DNA and how much of each, which points back at the source, whether that is diet, workplace, or the water supply.

Contaminated drinking water at Camp Lejeune went undiscovered for 34 years, and as many as a million people were exposed before the worst wells were shut down. Exposure is the part of cancer risk that is in principle avoidable and in practice invisible, because the standard tools tell you about a tumour that already exists rather than about the chemicals that are working on you now.

Survalence measures the exposure directly. Carcinogens leave adducts bound to DNA, and the CaSe assay reads which ones are there and in what quantity, which identifies where they are coming from. That turns prevention into something a person can act on, by changing a diet, a habit, a workplace or a water source, rather than a set of population-level averages. The science is the founder's own field, and the team around him works in DNA repair, adductomics and cancer prevention.

⟶ Others in the room

If Survalence Biosciences is your kind of company.

These founders pitched at the same startup events. The room is usually the reason people find each other.

⟶ Two ways in

Companies like this one are in the room every fortnight.

FOR FOUNDERSTake the stage yourself.Five minutes, real questions from the investors in the room, and a listing here afterwards if you want one. Boston runs on a steady rhythm.
Apply to pitch →Nights in Boston
FOR INVESTORSGet the next ones first.The Biweekly Drop sends the companies that stood out on stage, with what they are building and where they got to. Same format as this page.
Join the drop →Browse the directory